Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 32fludarabine phosphate 25Peripheral Blood Stem Cell Transplantation 25Busulfan 20Antilymphocyte Serum 19Tacrolimus 15Mycophenolic Acid 15Filgrastim 15Cyclosporine 15Methotrexate 14Melphalan 12Etoposide 12pembrolizumab 11Whole-Body Irradiation 10Radiotherapy 10Methylprednisolone 10Sirolimus 9Psychiatric Rehabilitation 8Nivolumab 8Bortezomib 8fludarabine 7Prednisone 7Flow Cytometry 7sargramostim 6romidepsin 6Vorinostat 6Gemcitabine 6Doxorubicin 6Cord Blood Stem Cell Transplantation 6aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × AFM13 × Dermatologic × Clear all
NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Columbia University

Phase 1/2 Completed
18 enrolled 9 charts
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡